`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`
`v.
`
`CIPLA LTD.,
`Patent Owner.
`
`
`Case. IPR2017-00807
`
`Patent 8,168,620
`
`
`
`
`
`
`PETITIONER’S MOTION TO SEAL
`
`
`
`
`
`
`
`Pursuant to 35 U.S.C. § 316(a)(1) and 37 C.F.R. §§ 42.14 and 42.54,
`
`Petitioner Argentum Pharmaceuticals LLC (“Argentum”) respectfully requests that
`
`
`
`the Board seal Exhibit 1145.
`
`I.
`
`Reasons for Relief Requested
`
`The parties have previously conferred and agreed upon the entry of a
`
`Protective Order in this case. Patent Owner’s Motion for Entry of Stipulated
`
`Protective Order and Motion to Seal, Paper 23. The Protective Order provides all
`
`of the protections of the Default Protective Order of this Board (Appendix B of the
`
`Office Patent Trial Practice Guide, 77 Fed. Reg. 48756, 48771 (Aug. 14, 2012)).
`
`II. Motion to Seal
`The standard for granting a motion to seal is “good cause.” 37 C.F.R.
`
`§ 42.54. The Office Patent Trial Practice Guide provides that “the rules aim to
`
`strike a balance between the public’s interest in maintaining a complete and
`
`understandable file history and the parties’ interest in protecting truly sensitive
`
`information.” 77 Fed. Reg. at 48760. Those rules “identify confidential
`
`information in a manner consistent with Federal Rule of Civil Procedure
`
`26(c)(1)(G), which provides for protective orders for trade secret or other
`
`confidential research, development, or commercial information.” Id. (citing 37
`
`C.F.R. § 42.54). “Where confidentiality is alleged as to some but not all of the
`
`information submitted to the [Patent Trial and Appeal Board (‘PTAB’ or ‘Board’)],
`
`1
`
`
`
`
`
`the submitting party shall file confidential and non-confidential versions of its
`
`submission, together with a Motion to Seal the confidential version setting forth
`
`the reasons why the information redacted from the non-confidential version is
`
`confidential and should not be made publicly available.” Id. at 48770.
`
`Argentum moves to seal Exhibit 1145 as a courtesy to Patent Owner because
`
`it is a declaration from one of Petitioner’s witness that cites to and discusses
`
`formulation details of Meda/Mylan’s Dymista® product that Patent Owner Cipla’s
`
`has designated as confidential, and is the subject of Cipla’s own motion to seal.
`
`Paper 23. A redacted, public copy of Exhibit 1145 is being concurrently submitted
`
`as Exhibit 1165.
`
`III. Certification of Conference with Opposing Party Pursuant to 37 C.F.R.
`§ 42.54
`
`The parties have conferred concerning the designation of the confidential
`
`information. Cipla does not oppose this motion.
`
`IV. Conclusion
`For the reasons stated above, Argentum respectfully requests that this
`
`Motion to Seal be granted.
`
`
`
`
`
`
`
`2
`
`
`
`
`
`Date: March 6, 2018
`
`
`
`
`
`RESPECTFULLY SUBMITTED,
`
`
`
`
`
`
`
`s/Michael R. Houston/
`Michael R. Houston.
`Reg. No. 58,486
`Counsel for Petitioner
`
`
`
`
`
`3
`
`
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a copy of the foregoing Motion to
`
`Seal was served on March 6, 2018 on Counsel for Patent Owner via electronic mail
`
`
`
`to the following:
`
`
`
`dvarughe-PTAB@skgf.com
` dsterlin-PTAB@skgf.com
` alarock-PTAB@skgf.com
` ueverett-PTAB@skgf.com
`
`
`
`
`
`
`Dated: March 6, 2018
`
`
`
`
`
`By: /Joseph P. Meara/
`
`Joseph P. Meara
`Reg. No. 44,932
`Counsel for Petitioner
`
`
`
`
`
`
`
`4
`
`